Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack

Boston Scientific (BSX) announced it will not meet its 2026 sales and profit forecasts due to a cyberattack disrupting operations. The incident, first identified on August 25, caused network outages affecting manufacturing and order processing. The company expects partial revenue recovery but remains uncertain about the full financial impact. Shares fell 2.3% in morning trading. BSX had previously forecast 2026 adjusted earnings of $3.28-$3.32 per share and 5.5%-6.5% sales growth. It plans to up

Boston Scientific fell 5.9% after a cyberattack disrupted operations, potentially missing Q3 and 2026 sales/earnings forecasts. Novartis US shares dropped 13.9% due to a failed drug study. Qualcomm rose 3.2% on an AI data center deal with Amazon. US markets declined amid oil price hikes and inflation concerns.

Boston Scientific (BSX) announced on 8 September 2026 that a cyberattack will likely prevent it from meeting 2026 sales and profit guidance. Shares fell 3.31% by 1400 GMT, extending a 20-day decline of 9.82%. The company first disclosed the incident on 26 August, initially unsure of material impact. Updated guidance will be provided on 28 October 2026.

Boston Scientific recalled its Infinion CX spinal cord stimulator lead due to mechanical stress causing 1,081 serious injuries. The FDA reported the recall on Sept. 3, with the company instructing customers to stop use and return the device. The lead is part of a system for managing chronic pain.

Boston Scientific (BSX) reported that a recent cyberattack will likely impact its Q3 and full-year sales growth and adjusted earnings, missing prior guidance. The attack disrupted operations, but the company is restoring systems and expects to recover some lost revenue. The full financial impact is still unknown, and the investigation is ongoing.

Boston Scientific revised its 2026 sales and profit forecasts due to a cyberattack that disrupted operations. The company expects to recover some lost revenue but remains uncertain about the full financial impact. Shares fell 2.1% premarket. The incident follows recent cyberattacks on other healthcare firms.